- Graduate
- Undergraduate
- Research
- News & events
- About us
- Student Commons
- Contact us
- Somers Research Group
- Faculty and Staff Resources
- Next Steps
- Incoming Students
- Spring 2020 Convocation
- The Roundtable
- Conversion Therapy Survey
- Fall 2020 Convocation
- RESET Team
- Spring 2021 Convocation
- Planetary Health Research Group
- The Breathe Project
Areas of interest
Financialization, politics of drug regulation, health policy, gene therapy products, venture capital, private equity fund investments, public private partnerships, biopharmaceutical governance, access to medicines in the Global South, financialization, regulatory innovation
Biography
Dr. Ipek Eren Vural is a political scientist. She holds a M.Sc. in European Studies from the London School of Economics and Political Science, United Kingdom, and a Ph.D. in Development Studies from the University of Sussex, United Kingdom. She is an Associate Professor of the Department of Political Science and Public Administration at the Middle East Technical University in Turkey. She is an Adjunct Professor in the Department of Political Science at the Dalhousie University, NS, Canada.
Dr. Eren Vural's research interests and teaching expertise lie primarily in comparative politics and public policy, with a particular specialization in social and health policies. She published broadly on pharmaceutical policy, the political economy of intellectual property rights and access to drugs in the Global South and North, politics of European social policy, and the impacts of financialization on households and health care policies.
Dr. Eren Vural's current research seeks to deepen the understanding of the relationship between financialization and governance. Focussing on Canada and Europe, she explores how the growing prominence of financial institutions, markets, and actors in the global economy, affect pharmaceutical governance, regulation, and innovation. Focussing on COVID-19 vaccines and therapeutics, her recent research titled "Regulatory Transparency of Pharmaceuticals at Health Canada" analyzed the impacts of financialization on regulatory modernization and public funding of innovation.
T I L